Fox2Now St. Louis

High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient

SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the ...
Nasdaq

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting ...
Seeking Alpha

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO, Oct. 24, 2024 ...
Morningstar

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food ...
MarketWatch

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo ...
KXAN

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia

SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, ...
FOX40 News

Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary ...

- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study (NCT06839235) dose escalation ongoing with ...
FOX31 Denver

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial ...

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug ...